A detailed history of Susquehanna International Group, LLP transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 113,806 shares of SAGE stock, worth $619,104. This represents 0.0% of its overall portfolio holdings.

Number of Shares
113,806
Previous 227,528 49.98%
Holding current value
$619,104
Previous $2.47 Million 66.8%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.02 - $13.08 $798,328 - $1.49 Million
-113,722 Reduced 49.98%
113,806 $820,000
Q2 2024

Aug 15, 2024

BUY
$10.58 - $17.9 $1.32 Million - $2.23 Million
124,408 Added 120.64%
227,528 $2.47 Million
Q1 2024

May 07, 2024

SELL
$18.62 - $26.95 $2.88 Million - $4.16 Million
-154,527 Reduced 59.98%
103,120 $1.93 Million
Q4 2023

Feb 14, 2024

BUY
$17.1 - $22.26 $3.43 Million - $4.46 Million
200,565 Added 351.36%
257,647 $5.58 Million
Q3 2023

Nov 14, 2023

BUY
$16.75 - $48.98 $444,159 - $1.3 Million
26,517 Added 86.76%
57,082 $1.17 Million
Q2 2023

Aug 11, 2023

SELL
$40.65 - $59.54 $4.48 Million - $6.57 Million
-110,284 Reduced 78.3%
30,565 $1.44 Million
Q1 2023

May 16, 2023

BUY
$37.27 - $46.57 $3 Million - $3.75 Million
80,504 Added 133.41%
140,849 $5.91 Million
Q4 2022

Feb 14, 2023

SELL
$32.2 - $43.61 $184,892 - $250,408
-5,742 Reduced 8.69%
60,345 $2.3 Million
Q3 2022

Nov 14, 2022

SELL
$32.28 - $43.27 $8,102 - $10,860
-251 Reduced 0.38%
66,087 $2.59 Million
Q2 2022

Aug 15, 2022

SELL
$27.52 - $37.99 $2.66 Million - $3.67 Million
-96,561 Reduced 59.28%
66,338 $2.14 Million
Q1 2022

May 16, 2022

BUY
$30.71 - $45.71 $1.14 Million - $1.7 Million
37,097 Added 29.49%
162,899 $5.39 Million
Q4 2021

Feb 14, 2022

SELL
$37.06 - $47.11 $710,440 - $903,098
-19,170 Reduced 13.22%
125,802 $5.35 Million
Q3 2021

Nov 15, 2021

BUY
$40.26 - $57.37 $4.6 Million - $6.55 Million
114,178 Added 370.78%
144,972 $6.42 Million
Q2 2021

Aug 11, 2021

BUY
$54.88 - $79.29 $72,716 - $105,059
1,325 Added 4.5%
30,794 $1.75 Million
Q1 2021

May 17, 2021

SELL
$70.65 - $96.76 $4.34 Million - $5.94 Million
-61,391 Reduced 67.57%
29,469 $2.21 Million
Q4 2020

Feb 16, 2021

BUY
$58.41 - $89.06 $1.27 Million - $1.93 Million
21,686 Added 31.35%
90,860 $7.86 Million
Q3 2020

Nov 16, 2020

SELL
$41.13 - $62.45 $4.33 Million - $6.58 Million
-105,339 Reduced 60.36%
69,174 $4.23 Million
Q2 2020

Aug 14, 2020

BUY
$25.95 - $43.15 $289,965 - $482,158
11,174 Added 6.84%
174,513 $7.26 Million
Q1 2020

May 15, 2020

BUY
$26.15 - $77.24 $3.2 Million - $9.45 Million
122,406 Added 299.04%
163,339 $4.69 Million
Q4 2019

Feb 14, 2020

BUY
$60.18 - $154.77 $808,638 - $2.08 Million
13,437 Added 48.87%
40,933 $2.96 Million
Q3 2019

Nov 14, 2019

BUY
$140.29 - $189.96 $1.86 Million - $2.52 Million
13,260 Added 93.14%
27,496 $3.86 Million
Q2 2019

Aug 16, 2019

BUY
$157.85 - $183.09 $1.05 Million - $1.22 Million
6,661 Added 87.93%
14,236 $2.61 Million
Q2 2019

Aug 14, 2019

SELL
$157.85 - $183.09 $4.42 Million - $5.13 Million
-28,026 Reduced 78.72%
7,575 $1.39 Million
Q4 2018

Feb 14, 2019

SELL
$81.94 - $139.71 $8.91 Million - $15.2 Million
-108,751 Reduced 75.34%
35,601 $3.41 Million
Q3 2018

Nov 14, 2018

SELL
$138.11 - $169.04 $5.54 Million - $6.78 Million
-40,129 Reduced 21.75%
144,352 $20.4 Million
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $25.6 Million - $32.1 Million
182,538 Added 9394.65%
184,481 $28.9 Million
Q1 2018

May 15, 2018

SELL
$152.15 - $192.33 $40 Million - $50.6 Million
-262,925 Reduced 99.27%
1,943 $313,000
Q4 2017

Feb 14, 2018

BUY
$60.72 - $167.34 $16.1 Million - $44.3 Million
264,868
264,868 $43.6 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.